million
sexual
transmit
infect
sti
acquir
day
global
etiotrop
drug
effect
control
infecti
diseas
therefor
dire
need
explor
altern
strategi
especi
base
regul
immun
system
review
discuss
ration
approach
develop
better
understand
toward
immunotherapeut
strategi
base
modul
immun
system
attempt
curb
elev
risk
infecti
diseas
hiv
hpv
hsv
high
preval
develop
monoclon
antibodi
vaccin
sever
immun
base
treatment
promis
altern
strategi
offer
new
opportun
erad
pathogen
dendrit
practic
prevent
treat
diseas
boost
suppress
stimul
immun
known
immunotherapi
though
antimicrobi
drug
develop
rapidli
recent
past
drug
narrow
spectrum
target
certain
group
microb
lead
increas
resist
hindranc
treatment
compel
scientist
investig
new
way
develop
effect
costeffect
treatment
especi
immunotherapi
alarm
increas
preval
immunocompromis
peopl
besid
boom
antimicrobi
resist
lack
novel
antimicrobi
agent
form
basi
develop
immunotherapeut
strategi
frequent
use
immunebas
therapi
infecti
diseas
span
use
cytokin
growth
factor
boost
natur
immun
increas
effector
cell
respons
restrain
infecti
diseas
introduct
antibodi
differ
organ
use
monoclon
antibodi
hyperimmuneglobulin
cytokin
differ
interleukin
interferon
centuri
wit
remark
discoveri
includ
antimicrobi
agent
chang
face
medic
practic
use
antibiot
prevent
vaccin
led
declin
major
endem
industri
countri
lesser
extent
develop
countri
howev
pathogen
develop
resist
antimicrobi
agent
develop
develop
countri
fig
last
centuri
infecti
diseas
lead
reason
morbid
mortal
develop
world
likewis
million
peopl
lost
live
differ
citi
europ
due
bacteri
viral
infect
edward
fig
evolut
infecti
diseas
microbi
resist
jenner
reach
first
mileston
control
infect
demonstr
immun
inocul
human
materi
extract
cowpox
lesion
basi
immunebas
therapi
date
back
emil
von
behr
shibasabura
kitasato
introduc
serum
therapi
success
cure
children
infect
diphtheria
use
hors
antisera
whenev
pathogen
gain
entri
host
immun
mediat
releas
activ
immun
system
initi
respons
control
infect
stimul
phagocyt
effector
cell
macrophag
neutrophil
elimin
infecti
agent
modul
immun
respons
reason
approach
control
infect
compar
antimicrobi
chemotherapi
immunotherapi
infecti
diseas
includ
modif
antigenspecif
respons
eg
use
interferon
mobil
immun
respons
pathogen
eg
use
cytokin
inhibitor
cytokin
minim
endorgan
damag
base
use
nonspecif
antiinflammatori
agent
eg
use
steroid
tabl
activ
immunotherapi
prove
effect
acut
infecti
diseas
efficaci
depend
upon
use
suitabl
target
antigen
optim
antigen
peptid
interact
antigen
present
cell
tcell
concurr
blockag
neg
regulatori
mechan
inhibit
immunotherapeut
impact
sever
differ
type
immun
respons
evolv
qualit
avoid
infect
eg
differ
subset
helper
cell
eg
tfh
follicular
helper
cell
secret
differenti
b
cell
gener
memori
b
cell
addit
memori
cell
consist
distinct
popul
effector
memori
cell
central
memori
cell
distinct
effector
function
along
home
capac
mammalian
immun
system
includ
innat
adapt
compon
cooper
protect
host
microbi
infect
innat
immun
sens
microb
use
patternrecognit
receptor
like
ctype
lectinlik
receptor
tolllik
receptor
cytosol
nodlik
receptor
rigilik
receptor
trigger
activ
adapt
immun
respons
antimicrobi
respons
adapt
immun
system
turn
activ
innat
effector
mechan
antigenspecif
manner
sever
differ
subset
function
distinct
dendrit
cell
also
present
prove
patternrecognit
receptor
dendrit
cell
determin
qualiti
magnitud
acquir
immun
foreign
agent
microb
integr
dendrit
cell
translat
antigen
specif
b
cell
boost
strength
persist
qualiti
adapt
immun
respons
passiv
immun
introduc
boy
diphtheria
inject
diphtheria
antitoxin
cure
antidiphtheria
serum
favour
result
got
public
accept
part
europ
serum
therapi
use
control
bacteri
infect
neisseria
meningitidi
streptococcu
pneumonia
sinc
centuri
practic
dump
due
toxic
associ
heterolog
sera
wherea
recent
advanc
develop
monoclon
antibodi
provid
new
insight
elimin
infecti
organ
passiv
immunotherapi
base
administr
immunoglobulin
either
combin
toxic
counterpart
molecul
involv
adopt
migrat
activ
immun
cell
effector
compon
act
host
neoplasm
cellular
therapi
includ
adopt
transfer
specif
sensit
cytotox
lymphocyt
nonspecif
activ
lak
lymphocyteactiv
killer
cell
passiv
immunotherapi
includ
use
tabl
immunotherapeut
strategi
infect
mobil
immun
use
vaccin
inactiv
vaccin
contain
kill
microb
stimul
bodi
immun
live
attenu
vaccin
contain
live
pathogen
reduc
virul
toxoid
vaccin
consist
pathogen
toxin
poison
made
harmless
elicit
immun
respons
host
subunit
vaccin
contain
antigen
part
instead
entir
microb
conjug
vaccin
combin
poor
polysaccharid
antigen
carrier
protein
belong
pathogen
dna
vaccin
genet
materi
directli
inject
live
host
effici
elicit
humor
cellular
immun
intraven
immunoglobulin
therapi
use
differ
clinic
trial
therapeut
prophylact
agent
infecti
diseas
variou
studi
prove
promis
altern
strategi
control
infect
intraven
immunoglobulin
prepar
made
igg
type
antibodi
recruit
virus
lymphoid
organ
present
b
cell
lead
activ
immun
respons
fig
immunocompromis
patient
suscept
chronic
infect
studi
demonstr
patient
primari
immunodefici
treat
doubl
amount
immunoglobulin
two
time
standard
dose
signific
decreas
sever
frequenc
infect
observ
treatment
patient
west
nile
viru
enceph
intraven
immunoglobulin
contain
high
titr
antibodi
found
effect
intraven
immunoglobulin
therapi
also
clear
viremia
reestablish
cytokin
balanc
patient
suffer
acut
infect
chronic
fatigu
syndrom
cytomegaloviru
parvoviru
viru
caus
glomerulopathi
transplant
kidney
introduct
intraven
immunoglobulin
prepar
transplant
elimin
risk
virus
intraven
immunoglobulin
prepar
individu
expos
hpv
hiv
hsv
outbreak
may
emerg
benefici
adjunct
therapi
inject
monoclon
antibodi
anoth
attract
techniqu
passiv
immunotherapi
trigger
recruit
lymphocyt
activ
complement
system
monoclon
antibodi
develop
far
immunolog
disord
cancer
treatment
wherea
monoclon
antibodi
infecti
diseas
still
progress
recent
develop
monoclon
antibodi
differ
strain
influenza
viru
rais
possibl
mitig
infecti
epidem
approv
monoclon
antibodi
palivizumab
synagi
lead
develop
gener
monoclon
antibodi
astrazenecamedimmun
respiratori
syncyti
viru
infect
infant
anoth
studi
suggest
clinic
trial
monoclon
antibodi
hendra
nipah
virus
anim
exhibit
convinc
result
likewis
antibodi
base
treatment
ebola
hiv
hpv
viru
clinic
trial
polyclon
antibodi
effici
provid
better
protect
infect
abil
target
differ
antigen
polymorph
serotyp
provid
excel
opportun
amelior
prognosi
emerg
infecti
diseas
neglect
tropic
diseas
well
addit
polyclon
antibodi
simultan
target
varieti
epitop
kill
pathogen
symphogen
introduc
effect
method
develop
antigenspecif
recombin
human
polyclon
antibodi
ie
symplex
tm
sympress
tm
techniqu
infecti
diseas
cancer
sympress
platform
use
mammalian
cell
line
express
high
level
singl
antibodi
molecul
develop
reproduc
robust
polyclon
antibodi
polyclon
antibodi
efficaci
appli
intox
envenom
rabi
rabbit
antirabi
viru
glycoprotein
g
polyclon
antibodi
catalog
number
induc
endocytosi
virion
polyclon
antibodi
caus
attach
viru
host
cellular
receptor
fusion
trigger
acid
ph
endosom
lead
conform
chang
glycoprotein
trimer
transmembran
glycoprotein
viral
attach
protein
promot
uptak
viru
infect
cell
act
target
host
humor
immun
respons
infect
two
individu
develop
rabi
total
filipino
recipi
f
ab
equin
rabi
immunoglobulin
erig
favirab
sanofi
pasteur
lyon
franc
per
guidelin
none
given
postexposur
prophylaxi
pep
strictli
limit
therapeut
option
avail
virus
therefor
polyclon
serum
therapi
soon
emerg
potent
effect
techniqu
viral
infect
base
sever
research
clinic
studi
demonstr
effect
animalderiv
polyclon
antibodi
base
treatment
target
differ
venom
toxin
infect
current
immunoglobulin
therapi
target
highli
pathogen
avian
influenza
virus
eg
new
target
polyclon
f
ab
immunoglobulin
therapi
mice
vivo
proofofconcept
studi
equin
polyclon
f
ab
hpai
highli
pathogen
avian
found
prevent
infect
intranas
hpai
attack
accord
anoth
studi
prior
prophylaxi
post
therapeut
administr
four
pepsin
digest
immunoglobulin
avian
influenza
equin
f
ab
prepar
exhibit
cytopath
effect
infect
cultur
mdck
madindarbi
canin
kidney
cell
provid
protect
mice
anoth
studi
surviv
rate
observ
influenzainfectedmic
intraven
infus
high
dose
lg
antiinfluenza
igg
seriou
advers
event
observ
phase
clinic
trial
carri
year
old
healthi
human
male
inject
polyclon
f
ab
hpai
likewis
mani
anim
base
studi
demonstr
clinic
efficaci
polyclon
antibodi
therapi
variou
neglect
tropic
viral
diseas
unimmun
hamster
inject
west
nile
virusimmun
hamster
antisera
h
h
west
nile
viru
challeng
protect
lifethreaten
west
nile
viru
infect
decreas
diseas
death
notic
marburg
ebola
filovirus
challeng
nonhuman
primat
inject
marburg
ebola
filovirus
specif
polyclon
antibodi
obtain
nonhuman
primat
surviv
flavovirus
exposur
likewis
similar
result
obtain
ebola
infect
mice
guinea
pig
monkey
inject
polyclon
sera
acquir
ebola
immun
mice
equin
f
ab
found
effect
hamster
mice
infect
sarscov
infect
signific
reduct
lung
viral
titr
observ
compar
control
immunoglobulin
therapi
act
broad
spectrum
antimicrobi
therapi
activ
class
infecti
organ
develop
kind
pathogen
human
bodi
abl
gener
antibodi
exist
pathogen
antibodi
encod
variabl
gene
element
assembl
combin
divers
gene
element
germlin
increas
possibl
antibodi
product
larg
number
antigen
induct
somat
mutat
antibodi
gene
lead
product
divers
specif
high
affin
antibodi
ii
therapeut
antibodi
develop
target
extracellular
pathogen
report
monoclon
antibodi
also
effect
intracellular
pathogen
eg
intracellular
virus
neutral
iga
monoclon
antibodi
iii
introduct
antibodi
bring
antimicrobi
action
use
differ
mechan
antibodi
direct
cellular
toxic
toxin
viral
neutral
opson
obstruct
microbi
attach
complement
activ
iv
pharmacokinet
immunoglobulin
isotyp
igg
demonstr
effect
antimicrobi
agent
half
life
day
good
tissu
penetr
power
half
life
murin
monoclon
antibodi
shorter
human
usual
trigger
human
antibodi
respons
human
monoclon
antibodi
humanmous
chimer
antibodi
synthet
antibodi
prepar
made
human
antibodi
protein
sequenc
maintain
antigen
bind
region
present
heterolog
antibodi
longer
halfliv
adopt
immunotherapi
extract
exvivo
activ
nativ
immun
cell
patient
follow
intraven
inject
human
bodi
target
infect
effect
effici
techniqu
build
immun
virus
cell
deplet
progress
lose
function
cancer
chronic
infect
therefor
effect
cell
respons
curb
tumor
viral
infect
henc
techniqu
either
provid
function
cell
base
adopt
immunotherapi
restor
endogen
immun
respons
explor
cell
play
key
role
cancer
viral
infect
wherea
function
support
cell
addit
cell
trigger
optim
bcell
respons
boost
innat
immun
therefor
adopt
immunoglobulin
strategi
base
exploit
cell
alon
associ
cell
effect
cancer
chronic
infect
tcell
immunotherapi
amelior
follow
strategi
cultur
condit
ex
vivo
tcell
expans
produc
cell
desir
phenotyp
novel
type
antigen
present
cell
cytokin
combin
abl
enough
produc
function
cell
peculiar
phenotyp
cell
genet
modifi
gener
cell
high
affin
toward
desir
antigen
introduc
chimer
antigen
receptor
along
specif
tcell
receptor
specif
charact
exampl
cell
defici
hiv
coreceptor
produc
hivinfect
patient
ii
adopt
immunotherapi
combin
immunotherapi
reconstitut
vivo
function
well
expans
transfer
cell
control
inhibitori
signal
prevent
exhaust
transfer
cell
studi
demonstr
viru
specif
cell
produc
respons
antigen
present
cell
along
unmanipul
cell
help
treatment
viral
infect
cytomegaloviru
hiv
ebola
viru
adenovirus
anticip
adopt
immunotherapi
imped
inhibitori
pathway
pathway
associ
adopt
tcell
therapi
lead
longterm
mainten
effect
immun
respons
elimin
cancer
chronic
infect
human
immunodefici
viru
lentiretroviru
caus
acquir
immuno
defici
syndrom
aid
destroy
immun
system
interact
varieti
differ
bodi
cell
viru
transmit
vertic
sexual
blood
hiv
infect
associ
progress
exhaust
cell
due
enhanc
destruct
diminish
product
cell
hiv
replic
lead
cell
death
syncytium
format
persist
infect
thu
creat
reservoir
viru
mani
cell
tissu
million
peopl
suffer
hiv
viru
million
die
sinc
begin
epidem
major
caus
morbid
mortal
develop
world
global
preval
hiv
million
increas
million
million
death
report
incid
decreas
due
expand
access
antiretrovir
therapi
sinc
last
mani
year
patient
hiv
treat
cart
combin
antiretrovir
therapi
ie
use
sever
antiretrovir
drug
suppress
replic
viru
viru
complet
erad
therefor
trend
shift
toward
practic
immun
base
treatment
limit
associ
combin
antiretrovir
therapi
transmiss
drug
resist
hiv
strain
emerg
multidrug
resist
cart
alway
restor
normal
cell
count
million
peopl
suffer
hiv
initi
condit
consid
lethal
wherea
combin
immunebas
therapeut
result
longer
life
span
infect
person
declin
viremia
limit
hiv
replic
inhibit
diseas
progress
trigger
cytotox
lymphocyt
mediat
clearanc
infect
cell
human
immunodefici
imped
activ
lymphocyt
lead
exhaust
cell
progress
immunodefici
within
initi
three
month
infect
high
concentr
antibodi
develop
differ
viral
protein
infect
patient
recent
studi
unfold
antibodi
cell
activ
helper
respons
lead
control
hiv
viru
sever
differ
immunotherapeut
approach
hiv
infect
current
studi
sever
novel
strategi
explor
discov
prevent
therapeut
vaccin
prevent
infect
current
therapeut
vaccin
approach
includ
administr
singl
multipl
antigen
hiv
dna
autolog
dendrit
cell
inactiv
whole
hiv
particl
deplet
viral
vector
like
poxvirus
alvachiv
fowlpox
mva
adenoviru
date
vaccin
shown
degre
efficaci
modest
efficaci
hiv
acquisit
observ
thai
phase
iii
clinic
trial
antibodi
respons
envelop
env
observ
plasma
obtain
individu
administ
alvachiv
prime
aidsvax
boost
peptid
microarray
analysi
six
subtyp
group
consensu
exhibit
vaccin
trigger
antibodi
respons
loop
second
variabl
multipl
subtyp
respons
evalu
elisa
surfac
plasmon
reson
use
linear
cyclic
loop
peptid
antibodi
respons
cyclic
week
postimmun
notic
vaccin
individu
vaccin
trigger
antibodi
target
region
second
loop
consist
conserv
epitop
earli
transmiss
event
involv
second
loop
interact
support
evid
antibodi
may
contribut
viral
inhibit
prevent
vaccin
direct
infect
develop
use
differ
recombin
envelop
protein
belong
differ
strain
anticip
product
neutral
antibodi
hiv
two
recombin
vaccin
bival
subtyp
bival
subtyp
bb
test
phase
none
two
vaccin
prove
efficaci
vaccin
trigger
product
neutral
bind
antibodi
neutral
antibodi
restrict
strain
use
vaccin
narrow
neutral
respons
due
delet
autoreact
precursor
b
cell
induc
develop
broadli
reactiv
neutral
antibodi
post
hoc
examin
exhibit
individu
carri
high
concentr
bind
block
antibodi
may
develop
consider
level
protect
acquisit
nonefficaci
recombin
envelop
vaccin
shift
focu
toward
develop
immun
respons
crossstrain
breadth
earli
viral
control
markedli
influenc
breadth
magnitud
earli
tcell
therefor
ctlbase
vaccin
cytotox
lymphocyt
vaccin
develop
primarili
target
postinfect
viremia
prevent
hiv
acquisit
anticip
cytotox
lymphocyt
respons
hiv
protein
induc
insert
hiv
gene
recombin
viral
vector
shuttl
gene
class
antigenpres
pathway
replic
defect
recombin
adenoviru
vector
clade
b
nefgagpol
insert
first
tcell
vaccin
underw
clinic
efficaci
trial
exhibit
signific
increas
cell
immun
respons
target
variabl
conserv
region
viru
therefor
issu
immun
cell
breadth
neutral
antibodi
breadth
still
howev
toler
safeti
efficaci
conserv
region
base
vaccin
regist
clinicaltrialsgov
research
design
distinct
tcell
immunogen
hivconsv
differ
function
conserv
region
proteom
encount
bodi
immun
use
heterolog
primeboost
combin
nonrepl
poxviru
nonrepl
simian
chimpanze
adenoviru
modifi
vaccinia
viru
ankara
plasmid
dna
vaccin
administr
combin
vaccin
elicit
high
frequenc
cell
capabl
inhibit
replic
exhibit
good
toler
safeti
togeth
high
immunogen
anoth
tcell
base
approach
adenoviru
vector
prime
dna
overcom
tcell
antibodi
breadth
problem
differ
strain
belong
major
clade
use
dna
vaccin
month
blend
six
plasmid
express
env
protein
clade
b
c
wherea
gag
pol
nef
clade
b
follow
adenoviru
vector
boost
month
lead
express
env
glycoprotein
clade
b
c
along
gagpol
fusion
protein
clade
b
clinic
studi
demonstr
cell
respons
toward
envelop
neutral
antibodi
trigger
antibodi
toward
hiv
provid
sound
proof
vaccin
reduc
hiv
acquisit
exhibit
efficaci
year
follow
year
alvachiv
canarypox
vector
prime
express
clade
e
env
along
clade
b
gag
pro
month
protein
boost
associ
alum
adjuv
clade
month
region
suscept
target
protect
antibodi
associ
vaccin
efficaci
regimen
immedi
demonstr
result
pox
protein
publicpriv
partnership
collabor
discov
poxprotein
regimen
subsaharan
africa
immunolog
respons
observ
peopl
south
africa
similar
respons
observ
thailand
alvac
vector
clade
c
env
insert
design
construct
bival
clade
c
recombin
current
vaccin
two
adjuv
clinic
trial
south
african
region
boost
immun
result
hvtn
phase
studi
pend
schedul
efficaci
evalu
trial
late
efficaci
trial
six
candid
vaccin
step
phambili
prove
vaccin
trial
effect
hiv
acquisit
antibodi
produc
respons
region
specif
subclass
mediat
adcc
antibodydepend
cellmedi
cytotox
accord
protect
acquisit
therapeut
vaccin
develop
amelior
immun
respons
order
amelior
hiv
infect
date
even
singl
therapeut
hiv
vaccin
approv
fda
instead
therapeut
vaccin
direct
hiv
infect
clinic
trial
evalu
efficaci
italian
nation
aid
center
develop
vaccin
direct
tat
transactiv
transcript
protein
virul
factor
play
signific
role
hiv
gene
express
progress
transmiss
diseas
tatspecif
antibodi
may
prevent
hiv
acquisit
transmiss
phase
studi
prove
tat
vaccin
immunogen
safe
phase
ii
trial
propos
tat
induc
restor
cell
number
memori
cell
consider
reduct
load
blood
observ
respons
tat
vaccin
phase
trial
studi
current
fortyeight
longterm
infect
peopl
suppress
viral
load
antiretrovir
therapi
cart
inject
tat
oyi
vaccin
prepar
clinic
outcom
phase
iiia
trial
show
decreas
extent
hiv
rna
rebound
cart
interrupt
studi
show
tat
vaccin
protect
activ
hivinfect
cell
vitro
combin
treatment
tat
oyi
vaccin
cart
found
increas
tcell
number
phase
iii
studi
conduct
south
africa
trial
registr
clinicaltrialsgov
unfold
tat
vaccin
induc
crossclad
neutral
antitat
antibodi
patient
differ
infect
virus
belong
differ
genet
background
adopt
cell
therapi
transfer
autolog
antigen
specif
lymphocyt
cell
hiv
infect
patient
hiv
specif
ctl
cytotox
lymphocyt
respons
play
import
role
control
hiv
infect
research
find
novel
approach
amelior
hivspecif
cytotox
lymphocyt
respons
attempt
achiev
longterm
viral
clearanc
research
studi
base
hematopoiet
stem
progenitor
cell
hspc
approach
report
use
protect
car
chimer
antigen
receptor
engin
immun
hiv
infect
patient
carmodifi
hspc
cell
chimer
antigen
receptor
modifi
hematopoiet
stem
progenitor
cell
differenti
function
cell
along
natur
killer
cell
resist
hiv
infect
lead
cessat
hiv
replic
therefor
prove
stem
cellbas
gene
therapi
chimer
antigen
receptor
car
effect
feasibl
strategi
treat
chronic
hiv
infect
modif
human
hspc
hematopoiet
stem
progenitor
cell
hivspecif
car
differenti
hiv
specif
cell
cell
lineag
abl
decreas
viral
load
vivo
hspcbase
approach
use
car
demonstr
safe
feasibl
mice
wherea
human
base
multipl
hspcbase
gene
therapi
aim
protect
cell
hiv
infect
current
trial
clinicaltrialsgov
identifi
potenti
toxic
advers
event
relat
use
car
studi
yet
therefor
futur
research
must
address
subject
special
featur
present
car
made
suitabl
candid
genet
modif
cell
individu
broad
reactiv
genet
divers
isol
minim
immunogen
potenti
freedom
hiv
entri
receptor
activ
high
potenc
viru
suppress
speak
valu
car
design
hiv
infect
associ
cytokin
product
cytokin
influenc
viral
replic
regul
immun
system
thu
contribut
toward
progress
acquir
immunodefici
syndrom
sever
cytokin
involv
immun
regul
exert
opposit
effect
like
stimul
cellular
immun
function
other
induc
product
antibodi
aid
character
divers
disturb
imbal
regul
cytokin
express
differ
cytokin
affect
express
replic
hiv
differ
product
thelper
type
cytokin
eg
antivir
interferonc
decreas
wherea
thelper
type
cytokin
eg
tumor
necrosi
factor
increas
ifna
ifnb
inhibit
replic
cell
mdm
monocyt
deriv
macrophag
inhibit
monocyt
deriv
macrophag
act
hivsuppressor
cytokin
tnfa
tnfp
trigger
replic
mdm
cell
macrophagecoloni
stimul
factor
stimul
mdm
provok
cell
act
hivinduct
cytokin
ifnc
granulocytemacrophag
colonystimul
factor
act
bifunct
cytokin
inhibitori
stimulatori
impact
infect
therefor
cytokin
therapi
may
suggest
new
way
prevent
progress
aid
patient
experi
signific
declin
cell
therapi
shown
improv
count
find
studi
contrast
previou
studi
suggest
supplementari
benefit
patient
levi
et
al
also
demonstr
consider
rise
cell
infect
individu
administ
combin
highli
activ
antiretrovir
therapi
memori
cell
count
natur
killer
cell
lymphocyt
express
higher
group
compar
control
administr
infect
individu
led
expans
cell
receptor
alpha
chain
amplifi
number
central
memori
cell
mark
decreas
product
virusinduc
interferon
ifn
interferona
produc
cell
ipc
observ
hiv
patient
studi
suggest
direct
link
interferona
produc
cell
ipc
control
hiv
replic
phase
iiiii
studi
show
lower
rate
hiv
progress
ifna
vaccin
recipi
anoth
studi
involv
patient
asymptomat
hiv
infect
administ
ifna
show
decreas
hiv
load
studi
patient
follow
studi
rang
month
patient
ifna
group
develop
aid
compar
patient
placebo
group
sever
research
character
isol
neutral
antibodi
target
thu
introduc
new
way
passiv
immun
vaccin
trial
anim
model
demonstr
neutral
antibodi
potent
enough
suppress
hiv
infect
human
monoclon
antibodi
target
bind
site
human
immunodefici
viru
likewis
monoclon
antibodi
prove
effect
suppress
hiv
infect
anim
model
monoclon
antibodi
act
potent
mediat
adcc
antibodi
depend
cellular
toxic
activ
play
import
role
prevent
hiv
acquisit
accumul
evid
suggest
administr
monoclon
antibodi
human
mice
result
suppress
viral
load
likewis
inject
cocktail
monoclon
antibodi
well
singl
glycandepend
monoclon
antibodi
caus
dramat
declin
plasma
viraemia
rhesu
monkey
chronic
infect
simianhumanimmunodefici
viru
human
monoclon
antibodi
success
pass
phase
clinic
trial
clinicaltrialsgov
identifi
bind
bind
site
neutral
laboratori
clinic
hiv
isol
recent
anoth
antibodi
report
boost
humor
immun
anim
human
human
base
follow
clinic
studi
complet
evalu
therapeut
potenti
monoclon
antibodi
current
way
number
dendrit
cell
blood
reduc
case
infect
revers
dendrit
cell
therapi
sever
evid
suggest
develop
dendrit
cell
base
vaccin
promis
approach
infect
signific
decreas
viral
load
observ
infect
individu
treat
dendrit
cell
base
vaccin
dendrit
cell
base
therapi
control
hiv
replic
elicit
tcell
respons
therefor
therapeut
vaccin
base
monocytederiv
dendrit
cell
feasibl
safe
effect
control
hiv
infect
vitamin
bind
protein
serum
gc
protein
act
precursor
princip
macrophag
activ
factor
maf
maf
precursor
activ
serum
gc
protein
either
lost
diminish
hiv
infect
individu
deglycosyl
gc
protein
alphanacetylgalactosaminidas
produc
hivinfect
cell
thu
hiv
infect
patient
macrophag
deglycosyl
gc
protein
inactiv
caus
immunsuppress
infus
gcmaf
hiv
infect
individu
effect
immun
strategi
lead
complet
elimin
viru
human
papillomavirus
hpv
dna
virus
caus
human
neoplasia
like
wart
cancer
human
papillomaviru
type
infect
anogenit
region
hpv
infect
preval
sexual
transmit
infect
common
type
worldwid
hpv
caus
number
cancer
cervic
cancer
oropharyng
cancer
anal
cancer
vulval
vagin
penil
cancer
drug
avail
directli
elimin
hpv
treatment
avail
hpv
associ
health
problem
like
gential
wart
cervic
chang
cervic
cancer
etc
scientist
look
new
opportun
develop
immunebas
treatment
reduc
hpv
associ
cancer
upsurg
immunobas
treatment
hpv
besid
chemotherapi
surgeri
radiat
immunotherapeut
approach
vaccin
excit
addit
control
precancer
diseas
cancer
clinic
epidemiolog
data
reveal
induct
tcell
respons
correl
clearanc
hpvassoci
lesion
induct
immun
respons
known
crucial
immunotherapi
hpv
regulatori
protein
target
viral
antigen
develop
potent
direct
vaccin
platform
form
basi
hpv
immunebas
treatment
especi
efficaci
vaccin
develop
virus
like
particl
vlp
hpv
use
vaccin
direct
hpv
associ
cancer
activ
natur
killer
cell
associ
dendrit
cell
induc
immun
respons
viral
infect
tumor
presenc
hpvvlp
natur
killer
cell
increas
matur
dendrit
cell
upregul
hladr
increas
secret
ifnc
cytotox
activ
hpv
amelior
function
natur
killer
cell
therefor
viruslik
particl
vaccin
prove
best
candid
control
hpvassoci
malign
food
drug
administr
approv
three
prophylact
vaccin
gardasil
quadrival
hpv
cervarix
highli
immunogen
reduc
risk
hpv
infect
vaccin
formul
base
use
viruslik
particl
origin
protein
resembl
hpv
multipli
due
absenc
genet
materi
hpv
vaccin
potent
enough
erad
malign
tumor
preexist
lesion
induc
cellular
immun
direct
hpvinfect
cell
express
earli
viral
protein
like
vaccin
rais
titer
serum
immunoglobulin
g
antibodi
direct
differ
hpv
type
secret
cervicovagin
region
discharg
microabras
epithelium
direct
differ
hpv
type
gardasil
human
papillomaviru
quadrival
recombin
vaccin
compos
viruslik
particl
obtain
capsid
protein
belong
hpv
type
vaccin
manufactur
merck
co
approv
vaccin
effect
genit
wart
precancer
lesion
vagin
precanc
cancer
vulvar
cervic
cancer
young
women
adolesc
individu
treat
intramascular
inject
three
dose
regimen
vaccin
prove
highli
immunogen
instig
persist
highhpv
antibodi
titer
phase
iii
trial
prove
efficaci
gardasil
young
women
male
femal
adolesc
gardasil
second
gener
merck
cervic
cancer
vaccin
approv
food
drug
administr
protect
anal
vagin
cervic
cancer
vaccin
effect
cancer
associ
hpv
type
genit
wart
associ
hpv
type
gener
vaccin
still
need
achiev
complet
protect
hpv
type
caus
cervic
cancer
cervarix
tm
manufactur
glaxosmithklin
bival
viruslik
particl
vaccin
effect
hpv
type
respons
cervic
cancer
vaccin
develop
use
insect
cell
infect
recombin
baculoviru
adjuv
consist
alum
combin
ligand
mpl
monophosphoryl
lipid
efficaci
trial
demonstr
vaccin
immunogen
efficaci
increas
neutral
antibodi
titer
thu
provid
protect
cervic
intraepitheli
neoplasia
lesion
cancer
caus
dendrit
cell
base
vaccin
anoth
novel
therapeut
paradigm
cure
hpvassoci
cancer
dendrit
cell
recogn
potent
antigen
present
cell
lead
induct
cell
respons
vitro
vivo
provid
new
way
treat
sever
human
malign
autolog
dendrit
cell
load
protein
may
stimul
b
cell
respons
patient
unrespons
standard
treatment
dc
base
vaccin
efficaci
cancer
patient
immunocompet
earli
stage
diseas
low
tumor
burden
sever
therapeut
cancer
vaccin
mainli
target
hpv
oncoprotein
clinic
trial
stimul
cell
immun
respons
tumor
specif
antigen
therebi
trigger
immun
target
cancer
cell
vaccin
direct
hpv
protein
cure
anal
cervic
cancer
dna
construct
trigger
product
interleukin
treat
cervic
cancer
hpv
type
vaccin
hpv
associ
cervic
precanc
detox
dna
vaccin
provid
protect
cervic
intraepitheli
neoplasia
tabl
immunomodul
includ
immunosuppress
immunostimulatori
agent
trigger
secret
cytokin
macrophag
tnfa
lead
increas
respons
antibodi
product
respons
improv
antigen
present
dendrit
cell
cellmedi
immun
use
clinic
cure
viral
infect
like
herp
simplex
viru
human
papillomaviru
cancer
lesion
immunocompromis
individu
antibodi
nivolumab
opdivo
pembrolizumab
keytruda
vagin
vulvar
cervic
cancer
antibodi
durvalumab
combin
tremelimumab
six
cancer
includ
cervic
cancer
antibodi
ipilimumab
yervoy
cervic
cancer
clinic
trial
develop
monoclon
antibodi
emerg
therapeut
strategi
cure
cancer
viral
infect
low
toxic
high
specif
activ
immun
system
studi
elucid
monoclon
antibodi
may
form
basi
effect
develop
immunotherapi
hpv
infect
sever
monoclon
antibodi
clinic
trial
bevacizumab
avastin
human
antivascular
endotheli
growth
factor
monoclon
antibodi
cervic
ovarian
cancer
humax
tfadc
antibodi
drug
conjug
studi
phase
iii
trial
attempt
cure
advanc
cancer
includ
cervic
cancer
immunotherapeut
treatment
base
infus
cytokin
insert
immunostimulatori
gene
tumor
cell
tabl
differ
form
hpv
therapeut
vaccin
clinic
trial
genom
follow
cytokin
base
vaccin
repres
novel
approach
therapi
hpv
associ
cancer
research
recent
propos
tumor
cell
caus
genet
modifi
dna
encod
immunostimulatori
molecul
specif
cytokin
gmcsf
use
vaccin
imped
tumor
growth
order
amelior
antigen
present
tumor
bear
patient
dendrit
cellbas
vaccin
load
hybrid
dendrit
tumor
cell
hpv
dna
also
success
employ
encourag
approach
still
studi
anoth
studi
suggest
target
hpv
oncoprotein
adopt
tcell
therapi
could
efficaci
strategi
hpvrelat
cancer
vagina
peni
vulva
cervic
anal
oropharynx
herp
simplex
virus
envelop
doubl
strand
dna
virus
two
serotyp
infect
orofaci
region
genit
region
infect
caus
herp
simplex
viru
preval
worldwid
signific
rate
neonat
morbid
mortal
attribut
herp
labiali
caus
herp
vulvovagin
caus
incid
rate
hsv
infect
neonat
per
live
birth
hsv
caus
number
infect
labiali
conjunctivitiskerat
gingivostomat
herpet
whitlow
eczema
herpeticum
herp
gladiatorum
enceph
balan
urethr
vulvovagin
extern
dysuria
hsv
infect
treat
antivir
agent
like
acyclovir
drug
therapi
associ
toxic
side
effect
emerg
drug
resist
strain
narrow
spectrum
drug
treatment
effect
initi
stage
infect
peopl
infect
infect
lesser
risk
acquir
still
infect
genit
infect
also
increas
risk
hiv
infect
immunobiolog
herp
simplex
viru
associ
infect
complic
humor
cell
mediat
immun
paramount
import
immunolog
respons
hsv
infect
due
plethora
evolutionari
chang
viru
evad
immun
system
maintain
latenc
caus
intermitt
reactiv
diseas
fact
limit
util
passiv
immun
control
hsv
infect
therefor
subject
develop
immunotherapeut
strategi
hsv
infect
still
studi
need
research
come
episod
develop
efficaci
therapeut
prophylact
vaccin
herp
viru
infect
proven
complic
due
complex
life
cycl
latenc
herp
simplex
poorli
understood
mechan
immun
control
primari
recurr
stage
diseas
previou
studi
describ
activ
innat
immun
virusspecif
helper
cytokin
like
gamma
interferon
prevent
recurr
diseas
wherea
regulatori
suppressor
cell
cytokin
eg
regul
immun
profil
therebi
allow
establish
recurr
diseas
replic
reactiv
viru
therefor
efficaci
vaccin
must
stimul
immun
defect
cytokin
product
especi
gylcoprotien
gd
gb
activ
cell
activ
cell
fact
form
basi
develop
herp
simplex
viru
type
glycoproteindsubunit
vaccin
adjuv
alum
lipid
induc
helper
cell
result
clinic
trial
phase
iii
exhibit
glycoprotein
vaccin
efficaci
genit
herp
seroneg
femal
wherea
effect
men
women
seroposit
seroneagt
anoth
studi
suggest
secret
glycoprotein
g
highli
efficaci
novel
agent
develop
prophylact
vaccin
control
associ
infect
experi
carri
guinea
pig
recombin
glycoprotein
gb
gd
formul
adjuv
use
immunotherapeut
agent
order
control
recurr
genit
herp
result
increas
antibodi
titer
support
fact
gbgd
immunotherapi
could
effect
hsv
associ
genit
infect
attenu
viru
design
provid
immunogen
infect
caus
mice
guinea
pig
howev
area
hsv
vaccin
develop
need
research
though
mechan
antibodi
treatment
infect
complet
elucid
passiv
immun
via
antibodi
emerg
promis
technolog
control
hsv
infect
howev
experiment
studi
human
yet
perform
sever
evid
suggest
passiv
transfer
serum
hyperimmun
may
effect
inhibit
spread
significantli
reduc
sever
infect
caus
virus
vitro
studi
defin
sever
mechan
includ
antibodydepend
cellmedi
cytotox
wherebi
antibodi
may
particip
destruct
viru
infect
cell
monoclon
antibodi
direct
glycoprotein
gc
gd
test
abil
passiv
immun
mice
order
target
acut
virusinduc
neurolog
diseas
studi
later
reveal
passiv
immun
monoclon
antibodi
mous
decreas
sever
diseas
pathogen
spread
likewis
nine
monoclon
antibodi
aim
hp
glycoprotein
gb
gc
gd
ge
also
evalu
mice
lead
blockag
hsv
viru
dissemin
monoclon
antibodi
hold
promis
futur
develop
novel
approach
treatment
hsv
infect
human
monoclon
antibodi
mab
administ
mice
result
inhibit
celltocel
viral
transmiss
key
mechan
escap
humor
immun
surveil
mab
found
neutral
hsv
fulli
independ
complement
orand
recruit
immun
effector
cell
highli
effici
manner
featur
guarante
clinic
develop
mab
treatment
hsv
infect
drugresist
immunocompromis
patient
compon
innat
immun
interferon
natur
killer
cell
macrophag
provid
protect
hsv
infect
cell
specif
ctl
cytotox
cell
domin
determin
protect
immun
fusion
protein
consist
human
truncat
glycoprotein
prove
efficaci
immunotherapeut
agent
elicit
immun
system
hsv
associ
genit
infect
anoth
experiment
protocol
demonstr
role
dendrit
cell
gener
protect
immun
adopt
transfer
virusspecif
cytotox
lymphocyt
proven
efficaci
safe
prevent
control
viral
infect
room
explor
expans
activ
protocol
util
gener
virusspecif
ctl
cytotox
lymphocyt
line
minimum
possibl
time
success
outcom
cart
cell
provid
strong
hope
control
infecti
diseas
anticip
immun
promis
clinic
outcom
avail
myriad
infecti
diseas
cancer
develop
polyclon
monoclon
antibodi
therapi
sever
neglect
tropic
widespread
diseas
current
investig
clinic
data
preclin
studi
highlight
potenti
immunotherapi
hpv
hsv
hiv
thu
provid
baselin
data
futur
research
infecti
diseas
major
caus
morbid
mortal
thu
pose
seriou
threat
live
drug
therapi
associ
seriou
consequ
emerg
drugresist
strain
toxic
sideeffect
therefor
trend
shift
toward
immunebas
therapi
reawaken
har
power
immun
system
provid
longlast
protect
therapeut
vaccin
adopt
cell
therapi
gmcsf
therapi
cytokin
therapi
monoclon
antibodi
explor
get
popular
treatment
hiv
hpv
associ
infect
immunocompromis
host
although
specif
immun
strategi
hsv
yet
develop
overal
progress
made
research
increas
understand
toward
complex
infect
caus
describ
lot
issu
explor
address
